<DOC>
	<DOCNO>NCT01811849</DOCNO>
	<brief_summary>A Double-blind Study Pharmacokinetic Properties BIOD-238 BIOD-250 Compared Humalog® Subjects Type 1 Diabetes</brief_summary>
	<brief_title>Pharmacokinetic Injection Site Toleration BIOD-238 BIOD-250 Compared Humalog® Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>The purpose study assess speed absorption BIOD-238 BIOD-250 compare Humalog® . Secondary objective assess pharmacokinetic characteristic BIOD-238 BIOD-250 compare Humalog® , evaluate safety tolerability BIOD-238 BIOD-250 compare Humalog® .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Age : ≥18 ≤70 year Body Mass Index : ≥18 ≤35 kg/m2 Diagnosed Type 1 Diabetes Mellitus least 1 year Type 2 diabetes mellitus Serum Cpeptide &gt; 1.0 ng/mL HbA1c &gt; 10.0 % History hypersensitivity component study medication Treatment investigational drug last 30 day dose . Current drug alcohol abuse , history drug alcohol abuse opinion Investigator impair subject safety , protocol compliance , interpretation study result . Caffeine , nicotine alcohol addiction might expect result withdrawal symptom course study dose day would fall category .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>diabetes</keyword>
</DOC>